Advertisement

Breast Cancer Symposium - Enhancing Clinical Care Through Collaboration

2012 Program Agenda

2012 Breast Cancer Symposium Program Agenda

Jump to Day: Thursday | Friday | Saturday

 

 

  Thursday September 13, 2012

7:00 AM — 7:00 PM

Exhibits Open

7:00 AM — 7:45 AM

Continental Breakfast Provided

7:45 AM — 9:00 AM

Welcome and General Session I: Controversial Topics in Medical Oncology Management

Chair: Lori Goldstein, MD – Fox Chase Cancer Center 

  • ABSTRACT #98: Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
    Mark D. Pegram, MD - Stanford University
     
  • ABSTRACT #99: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
    Francis P. Arena, MD - Arena Oncology Associates
     
  • Role of mTOR Inhibitors in Metastatic Disease
    William John Gradishar, MD – Northwestern University
     
  • Role of Chemotherapy for Small TN and HER2+ Cancers
    Robert Carlson, MD – Stanford Comprehensive Cancer Center

9:00 AM — 9:30 AM

Break

9:30 AM — 11:00 AM

General Session II: Risk Assessment, Prevention, Detection, and Screening

Chair: Banu Arun, MD – M. D. Anderson Cancer Center

  • ABSTRACT #1: Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28.
    Eleftherios P. Mamounas, MD - Aultman Hospital
     
  • ABSTRACT #2: Correlation of receptor activator of nuclear factor kappa b (RANK) expression in breast cancer (BC) at the time of diagnosis with recurrence-free survival (RFS) and risk of bone-dominant metastases (BDM) in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657).
    Jiali Li, MD, PhD - University of California, San Francisco Helen Diller Family Comprehensive Cancer Center

  • What is High Risk, What is the Definition of Genetic Testing, and What To Do With the Results
    Claudine Isaacs, MD – Georgetown University
     
  • Imaging Techniques: What Works, What Doesn’t
    David A. Mankoff, MD, PhD - University of Washington
                                           
  • The Value of Risk-Reducing Surgery for Premalignant Lesions, DCIS, ADH
    Todd M. Tuttle, MD, MS – University of Minnesota
     
  • Medical Management and Prevention of Premalignant Lesions in Ductal Carcinoma in Situ, LCIS, ADH
    Victor Vogel, MD, MHS – Geisinger Health System

 

11:00 AM — 1:00 PM

General Poster Session A

(with complimentary boxed lunch)

View Abstract Titles

Topics will include:

General Screening
Genomics
High Risk
Ductal Carcinoma in Situ
Management of Node Positive Disease

Selected abstracts will be on display in the General Poster Session and then discussed in the Poster Discussion Session at 4:30 PM.

 

11:10 AM — 11:40 AM

Poster Walks

(four groups) 

Seema Khan, MD – Northwestern University
Meena S. Moran, MD - Yale University School of Medicine
Lori Pierce, MD – University of Michigan
Shawna Willey, MD – Georgetown University  

11:45 AM — 12:45 PM

Tumor Board

Moderator: Lori J. Pierce, MD – University of Michigan

Panelists:
Lori J. Pierce, MD – University of Michigan
Shawna Willey, MD – Georgetown University
Daniel Hayes, MD – University of Michigan
Anna Maria Storniolo, MD – IU Simon Cancer Center
Kathryn Evers, MD - Fox Chase Cancer Center  

1:00 PM — 2:15 PM

General Session III: Controversies in Diagnosis of Early Stage Breast Cancer and Management of Sentinel Nodes

Chairs: Jennifer Bellon, MD – Dana-Farber Cancer Institute; Richard Bleicher, MD – Fox Chase Cancer Center

  • MRI Debate  Moderator: Richard Bleicher, MD – Fox Chase Cancer Center
    Pro: Constance D. Lehman, MD, PhD, FACR – Seattle Cancer Care Alliance
    Con: Kathryn Evers, MD – Fox Chase Cancer Center
  • Panel Discussion: Reconciling the Z0011 Approach to Nodal Management of Sentinel Node-Positive Disease with MA.20 - use of the Audience Response System (ARS)
    Case Presentations: Jennifer Bellon, MD – Dana-Farber Cancer Institute Surgeon: Monica Morrow – MD – Memorial Sloan-Kettering Cancer Center
    Surgeon: Michael S. Sabel, MD – University of Michigan
    Radiation Oncologist: Reshma Jagsi, MD – University of Michigan Radiation Oncologist: Alice Ho, MD - Memorial Sloan-Kettering Cancer Center

2:15 PM — 2:45 PM

Break

2:45 PM — 4:15 PM

General Session IV: Controversies in Local/Regional Treatment

Chairs: Lori Pierce, MD – University of Michigan; Robert Kuske, MD – Arizona Breast Cancer Specialists

  • ABSTRACT #143: Intraoperative electron radiotherapy in early-stage breast cancer: A report on 226 patients.
    Stefano dall'Oglio, MD - University Hospital
     
  • Intraoperative Radiation Therapy: Analysis of a Randomized Trial
    Jayant Vaidya, PhD – University College London
     
  • Intraoperative Radiation Therapy: A Practical Perspective
    Julia White, MD - The Stefanie Spielman Comprehensive Breast Center
     
  • ABSTRACT #144: Reduced re-excisions while conserving tissue volume resected in DCIS patients.
    Beth Cutler Freedman, MD - Beth Israel Medical Center
     
  • Debate on Role of Local Radiation Therapy in Ductal Carcinoma in Situ
    Moderator: Robert Kuske, MD – Arizona Breast Cancer Specialists
    Pro: Thomas B. Julian, MD – Drexel University College of Medicine
    Con: Abram Recht, MD - Beth Israel Deaconess Medical Center

4:15 PM — 4:30 PM

Break

4:30 PM — 5:30 PM

Poster Discussion Session A

Topics will include: Risk Assessment, Prevention, Detection, and Screening Local/Regional Therapy Chair: Bruce Haffty, MD – The Cancer Institute of New Jersey

  • Imaging/High Risk Discussion (Abstracts #3-7)
    Thomas A. Buchholz, MD, FACR - MD Anderson Cancer Center
     
  • Genetic/Path Discussion (Abstracts #8-11)
    Banu Arun, MD – M. D. Anderson Cancer Center
     
  • Partial Breast Irradiation Discussion (Abstracts #145-149)
    Robert Kuske, MD – Arizona Breast Cancer Specialists
     
  • Surgical Issues Discussion (Abstracts #150-153)
    Sarah A. McLaughlin, MD – Mayo Clinic  

5:30 PM — 7:00 PM

General Poster Session A (Continued)
(with complimentary wine and cheese reception)

View Abstract Titles

Topics will include:

General Screening
Genomics
High Risk
Ductal Carcinoma in Situ
Management of Node Positive Disease
 

Friday, September 14, 2012

7:00 AM — 7:00 PM

Exhibits Open

7:00 AM — 8:00 AM

Continental Breakfast Provided

7:00 AM — 8:00 AM

 Meet the Professor Sessions

(Three concurrent sessions)

  • Management of the Clinically Negative Axilla
    Monica Morrow, MD – Memorial Sloan-Kettering Cancer Center
  • Reassessing Local Treatment in the Context of Increasingly Effective Systemic Therapy
    Jay R. Harris, MD – Dana-Farber Cancer Institute
  • Marker-driven Personalized Therapy of Breast Cancer
    Gabriel N. Hortobagyi, MD – M. D. Anderson Cancer Center

8:00 AM — 9:15 AM

Welcome and General Session V: Genomics for the Clinician

Chair: Mark D. Pegram, MD - Stanford University

  • The Genomic Landscape of Breast Cancer
    Matthew J. Ellis, MD – Washington University
  • Clinical Trials Based on Detection of Somatic Mutations in Advanced Disease 
    Mark D. Pegram, MD - Stanford University
  • Clinical Trials Based on Genomic Profiling in the Adjuvant and Neoadjuvant Setting
    Ana Maria Gonzalez, MD – M. D. Anderson

9:15 AM — 9:45 AM

Break

9:45 AM — 10:30 AM

ASCO Gianni Bonadonna Breast Cancer Award and Lecture

2012 Awardee is Monica Morrow, MD - Memorial Sloan-Kettering Cancer Center  

10:30 AM — 11:15 AM

General Session VI: Healthcare Delivery and Prevention

Chair: Bruce Haffty, MD - The Cancer Institute of New Jersey

  • Breast Healthcare Delivery in Context: The World Health Organization's Initiative for Noncommunicable Diseases
    Benjamin O. Anderson, MD - Fred Hutchinson Cancer Research Center
     
  • Reducing Breast Cancer Risk: Progress toward Resolution
    Rowan T. Chlebowski, MD, PhD - David Geffen School of Medicine at UCLA

11:15 AM — 1:15 PM

General Poster Session B

(with complimentary boxed lunch provided)

View Abstract Titles

Topics will include:

Survivorship
HER2+
Triple-Negative
Biology in Local/Regional Management

Selected abstracts will be on display in the general poster session and then discussed in the poster Discussion session at 4:45 PM.

11:30 AM — 1:00 PM

Poster Walks 

(Six groups)

11:30 AM - 12:00 PM
Lori Goldstein, MD – Fox Chase Cancer Center
Sandhya Pruthi, MD – Mayo Clinic

12:00 PM - 12:30 PM
Hope S. Rugo, MD – UCSF Helen Diller Family Comprehensive Cancer Center William Sikov, MD – Brown University
Kathy S. Albain, MD - Loyola University

12:30 PM - 1:00 PM
Melinda Telli, MD – Stanford University
 

1:15 PM — 2:45 PM

General session VII: Survivorship

Chair: Kathy S. Albain, MD - Loyola University; Sandra M. Swain, MD – Washington Cancer Institute

  • ABSTRACT #61: Making it work: Breast cancer survivorship care at Johns Hopkins.
    Elissa Thorner Bantug, MHS - Johns Hopkins University
     
  • ABSTRACT #62: Risk of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after adjuvant chemotherapy (CT) for early breast cancer (BC) in the community setting.
    Neelima Denduluri, MD - Virginia Cancer Specialists, US Oncology
  • Transition from Active Treatment to “Normal Life” as a Survivor
    Denise O'Neill - Survivors Offering Support   
  • Obesity in Survivorship
    Patrick Morris, MD – Memorial Sloan-Kettering Cancer Center
  • Managing Menopausal Symptoms in Patients with Breast Cancer
    Patrick Neven, MD – Leuven Cancer Institute
  • Quality Measures in Survivorship
    Ann H. Partridge, MD, MPH – Dana-Farber Cancer Institute

2:45 PM — 3:15 PM

Break

3:15 PM — 4:30 PM

General Session VIII: The Future of Health Policy

Chair: Richard L. White, Jr., MD – Blumenthal Cancer Center

  • Reducing Disparities
    Claudia R. Baquet, MD, MPH – University of Maryland School of Medicine
  • What Are the Differences between Using a New Drug and a New Technology
    Gary H. Lyman, MD, MPH - Duke University School of Medicine
  • Rapid Learning Systems
    Sandra M. Swain, MD – Washington Cancer Institute

4:30 PM — 4:45 PM

Break

4:45 PM — 5:45 PM

Poster Discussion Session B

Topics will include: Survivorship and Health Policy Systemic Therapy

Chair: Malcolm R. Kell, MD, FRCS – Mater Misericordiae University Hospital

  • Disparities Discussion (Abstracts #63-66)
    Krystyna D. Kiel, MD – Rush University Medical Center
     
  • Survivorship Concerns Discussion (Abstracts #67-69)
    Cornelia Liedtke, MD - University of Meunster
     
  • Endocrine Resistance Discussion (Abstracts #102-105)
    Matthew J. Ellis, MD – Washington University
     
  • Triple-negative Disease Discussion (Abstracts #106-109)
    Melinda L. Telli, MD – Stanford University

5:45 PM — 7:00 PM

General Poster Session B (Continued)

(with complimentary wine and cheese reception)

View Abstract Titles

Topics will include:

Survivorship
HER2+
Triple-Negative
Biology in Local/Regional Management
 

Saturday, September 15, 2012

6:30 AM — 7:30 AM

Fellows, Residents, and junior faculty networking breakfast

Chairs: Hope S. Rugo, MD – UCSF Helen Diller Family Comprehensive Cancer Center; Meena S. Moran, MD - Yale University School of Medicine
 

6:30 AM — 8:00 AM

General poster session c

(with complimentary breakfast provided)

View Abstract Titles

Topics will include:

Health Policy
Advanced Disease
 

8:00 AM — 9:30 AM

welcome and General Session IX: New directions in systemic therapy for advanced Disease

Chairs: Heather McArthur, MD. MPH – Memorial Sloan-Kettering Cancer Center; Eric P. Winer, MD – Dana-Farber Cancer Institute  

  • ABSTRACT #100: Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC). 
    Adam M. Brufsky, MD, PhD - University of Pittsburgh Cancer Institute 
  • An Update on HER2-Positive Breast Cancer
    Mark D. Pegram, MD - Stanford University (Given by Hope S. Rugo, MD - UCSF Helen Diller Family Comprehensive Cancer Center)
  • Hormone-Responsive Disease
    Francisco J. Esteva, MD, PhD – M. D. Anderson Cancer Center
  • Treatment Strategies for Patients with Triple-Negative Breast Cancer
    Lisa A. Carey, MD – Lineberger Comprehensive Cancer Center
     
  • Panel Discussion
    Moderator: Eric P. Winer, MD – Dana-Farber Cancer Institute

9:30 AM — 9:50 AM

Break and Poster Session C (continued)

View Abstract Titles

Topics will include:

Health Policy
Advanced Disease
 

9:50 AM — 10:40 AM

General Session X: Health Policy: opportunities and Challenges

Chair: Richard L. White, Jr., MD - Blumenthal Cancer Center

  • Opportunities Lost
    Otis W. Brawley, MD - American Cancer Society
     
  • Drug Shortages in Breast Cancer
    Thomas Kornberg, PhD - UCSF Helen Diller Family Comprehensive Cancer Center

10:40 AM — 11:00 AM

Break and Poster Session C (continued)

Topics will include:
Health Policy
Advanced Disease
 

11:00 AM — 12:30 PM

General Session XI: Debates on Current Controversies in Systemic Therapy

Chairs: Gabriel N. Hortobagyi, MD – M. D. Anderson Cancer Center; Minetta C. Liu, MD – Georgetown University

  • Use of Anthracyclines in HER2-Positive and HER2-Negative Patients Moderator: Gabriel N. Hortobagyi, MD – M. D. Anderson Cancer Center
    Pro: Clifford A. Hudis, MD – Memorial Sloan-Kettering Cancer Center
    Con: Stephen E. Jones, MD - US Oncology Research
     
  • Bone Health/Role of Bisphosphonates in Early-Stage Breast Cancer Moderator: Minetta C. Liu, MD - Georgetown University 
    Pro: Catherine Hall Van Poznak, MD – University of Michigan
    Con: Julie R. Gralow, MD – Seattle Cancer Care Alliance

12:30 PM

Adjourn

 

 

 

Cosponsored by